Mauricio Bedoya

Dr. Mauricio Bedoya

Universidad de Talca
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2015
Verified
Book Chapter
Open access
PDF file
JRJhon Rojas
Jhon Rojas
MBMauricio Bedoya
Mauricio Bedoya
YCYhors Ciro
Yhors Ciro
Current Trends in the Production of Cellulose Nanoparticles and Nanocomposites for Biomedical Applications | InTechOpen, Published on: 2015-12-09. Authors: John Rojas, Mauricio Bedoya and Yhors Ciro

6 March 2021 in Cellular Physiology and Biochemistry
Verified
Journal Article
Closed access
PDF file
Niels DecherNiels Decher
Niels Decher
SRSusanne Rinné
Susanne Rinné
MBMauricio Bedoya
Mauricio Bedoya
WGWendy Gonzalez
Wendy Gonzalez
AKAytug K. Kiper
Aytug K. Kiper
Potassium channels of the tandem of two-pore-domain (K2P) family were among the last potassium channels cloned. However, recent progress in understanding their physiological relevance and molecular pharmacology revealed their therapeutic potential and thus these channels evolved as major drug targets against a large variety of diseases. However, after the initial cloning of the fifteen family members there was a lack of potent and/or selective modulators. By now a large variety of K2P channel modulators (activators and blockers) have been described, especially for TASK-1, TASK-3, TREK-1, TREK2, TRAAK and TRESK channels. Recently obtained crystal structures of K2P channels, alanine scanning approaches to map drug binding sites, in silico experiments with molecular dynamics simulations (MDs) combined with electrophysiological studies to reveal the mechanism of channel inhibition/activation, yielded a good understanding of the molecular pharmacology of these channels. Besides summarizing drugs that were identified to modulate K2P channels, the main focus of this article is on describing the differential binding sites and mechanisms of channel modulation that are utilized by the different K2P channel blockers and activators.

26 February 2019 in eLife
Verified
Journal Article
Open access
SRSusanne Rinné
Susanne Rinné
Aytug Kadir KiperAytug Kadir Kiper
Aytug Kadir Kiper
KVKirsty S Vowinkel
Kirsty S Vowinkel
David RamirezDavid Ramirez
David Ramirez
MSMarcus Schewe
Marcus Schewe
Niels DecherNiels Decher
Niels Decher
Two-pore-domain potassium (K2P) channels are key regulators of many physiological and pathophysiological processes and thus emerged as promising drug targets. As for other potassium channels, there is a lack of selective blockers, since drugs preferentially bind to a conserved binding site located in the central cavity. Thus, there is a high medical need to identify novel drug-binding sites outside the conserved lipophilic central cavity and to identify new allosteric mechanisms of channel inhibition. Here, we identified a novel binding site and allosteric inhibition mechanism, disrupting the recently proposed K+-flux gating mechanism of K2P channels, which results in an unusual voltage-dependent block of leak channels belonging to the TASK subfamily. The new binding site and allosteric mechanism of inhibition provide structural and mechanistic insights into the gating of TASK channels and the basis for the drug design of a new class of potent blockers targeting specific types of K2P channels.

1 July 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMauricio Bedoya
Mauricio Bedoya
SRSusanne Rinné
Susanne Rinné
Aytug Kadir KiperAytug Kadir Kiper
Aytug Kadir Kiper
NDNiels Decher
Niels Decher
WGWendy González
Wendy González
David RamirezDavid Ramirez
David Ramirez

19 April 2019 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
FWFelix Wiedmann
Felix Wiedmann
Aytug Kadir KiperAytug Kadir Kiper
Aytug Kadir Kiper
MBMauricio Bedoya
Mauricio Bedoya
ARAntonius Ratte
Antonius Ratte
SRSusanne Rinné
Susanne Rinné
CSConstanze Schmidt
Constanze Schmidt
The two-pore-domain potassium channel TASK-1 regulates atrial action potential duration. Due to the atrium-specific expression of TASK-1 in the human heart and the functional upregulation of TASK-1 currents in atrial fibrillation (AF), TASK-1 represents a promising target for the treatment of AF. Therefore, detailed knowledge of the molecular determinants of TASK-1 inhibition may help to identify new drugs for the future therapy of AF. In the current study, the molecular determinants of TASK-1 inhibition by the potent and antiarrhythmic compound A293 (AVE1231) were studied in detail. Alanine-scanning mutagenesis together with two-electrode voltage-clamp recordings were combined with in silico docking experiments. Here, we have identified Q126 located in the M2 segment together with L239 and N240 of the M4 segment as amino acids essential for the A293-mediated inhibition of TASK-1. These data indicate a binding site which is different to that of A1899 for which also residues of the pore signature sequence and the late M4 segments are essential. Using in silico docking experiments, we propose a binding site at the lower end of the cytosolic pore, located at the entry to lateral side fenestrations of TASK-1. Strikingly, TASK-1 inhibition by the low affinity antiarrhythmic TASK-1 blockers propafenone, amiodarone and carvedilol was also strongly diminished by mutations at this novel binding site. We have identified the A293 binding site in the central cavity of TASK-1 and propose that this site might represent a conserved site of action for many low affinity antiarrhythmic TASK-1 blockers.

Verified
Journal Article
Open access
PDF file
David RamirezDavid Ramirez
David Ramirez
MBMauricio Bedoya
Mauricio Bedoya
Aytug Kadir KiperAytug Kadir Kiper
Aytug Kadir Kiper
SRSusanne Rinné
Susanne Rinné
SNSamuel Morales Navarro
Samuel Morales Navarro
WGWendy González
Wendy González
TASK-3 potassium (K+) channels are highly expressed in the central nervous system, regulating the membrane potential of excitable cells. TASK-3 is involved in neurotransmitter action and has been identified as an oncogenic K+ channel. For this reason, the understanding of the action mechanism of pharmacological modulators of these channels is essential to obtain new therapeutic strategies. In this study we describe the binding mode of the potent antagonist PK-THPP into the TASK-3 channel. PK-THPP blocks TASK-1, the closest relative channel of TASK-3, with almost nine-times less potency. Our results confirm that the binding is influenced by the fenestrations state of TASK-3 channels and occurs when they are open. The binding is mainly governed by hydrophobic contacts between the blocker and the residues of the binding site. These interactions occur not only for PK-THPP, but also for the antagonist series based on 5,6,7,8 tetrahydropyrido[4,3-d]pyrimidine scaffold (THPP series). However, the marked difference in the potency of THPP series compounds such as 20b, 21, 22 and 23 (PK-THPP) respect to compounds such as 17b, inhibiting TASK-3 channels in the micromolar range is due to the presence of a hydrogen bond acceptor group that can establish interactions with the threonines of the selectivity filter.